From left to right: Drs. Anne-Claude Gingras, Mikko Taipale and Daniel Schramek.
Researchers at the University of Toronto and Sinai Health have devised a new molecular platform to identify proteins involved in disease and potentially target them for therapy.
The Senior Investigators Drs. Anne-Claude Gingras and Daniel Schramek from the Lunenfeld-Tanenbaum Research Institute, part of Sinai Health, contributed to the study, which was led by Dr. Mikko Taipale from U of T’s Donnelly Centre for Cellular and Biomedical Research, and reported in the journal Nature.
To find out more about this research, read the Donnelly Centre story.
Globally renowned for her research in functional proteomics, Dr. Gingras is also the Director of LTRI and Vice President of Research for Sinai Health, while Dr. Schramek is a leader in functional genomics and the Deputy Director of Discovery Research for Sinai Health.